

Full Spectrum Flow Cytometry: Powerful Technology for Cancer Immunotherapy †

Dian L. Bonilla ¹, Gil Reinin ¹, Edmond Chua ^{1,*}

¹ Cytex Biosciences, Fremont, CA, United States

* Correspondence: pasculli@acela.eu;

† Presented at 1st OncoHub Conference – Connecting Scientists for Next Generation Cancer Management (13-15 October 2021, virtual)

Received: 25.10.2021; Accepted: 5.02.2022; Published: 14.02.2022

Abstract: Flow cytometry has been fundamental in diagnosis, treatment, and translational research in cancer clinical trials. Most recently, the need to evaluate simultaneously more features in each cell has pushed the field to implement more powerful adaptations beyond conventional flow cytometry, including Full Spectrum Flow Cytometry (FSFC). Cytex FSFC captures the full emission spectrum of fluorescent molecules using arrays of highly sensitive light detectors and to date, has enabled the characterization of 40 parameters in a single sample. The Cytex spectral technology leverages full-spectrum technology to provide unprecedented flexibility to scientists, enabling the use of a wide array of new fluorochrome combinations without reconfiguring the system for each application. The Aurora system delivers high-resolution data at the single-cell level to resolve the most challenging cell populations, such as cells with high autofluorescence or low expression levels of key biomarkers, regardless of assay complexity.

Keywords: spectral flow cytometry; immunoncology; cancer therapy.

© 2022 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Funding

This presentation was sustained by OncoHub conference sponsor Accela.

Acknowledgments

This research has no acknowledgment.

Conflicts of Interest

The authors declare no conflict of interest.